deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
Company profile
Ticker
DCPH
Exchange
Website
CEO
Steven Hoerter
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Deciphera Pharmaceuticals, LLC
SEC CIK
Corporate docs
Subsidiaries
Deciphera Pharmaceuticals, LLC • Deciphera Pharmaceuticals Securities Corporation ...
DCPH stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
7 Feb 24
10-K
2023 FY
Annual report
7 Feb 24
8-K
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results
6 Feb 24
8-K
Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company
8 Jan 24
UPLOAD
Letter from SEC
2 Jan 24
CORRESP
Correspondence with SEC
22 Dec 23
UPLOAD
Letter from SEC
14 Dec 23
10-Q
2023 Q3
Quarterly report
30 Oct 23
8-K
Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results
30 Oct 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
Transcripts
DCPH
Earnings call transcript
2023 Q4
6 Feb 24
DCPH
Earnings call transcript
2023 Q3
30 Oct 23
DCPH
Earnings call transcript
2023 Q2
9 Aug 23
DCPH
Earnings call transcript
2023 Q1
3 May 23
DCPH
Earnings call transcript
2022 Q4
7 Feb 23
DCPH
Earnings call transcript
2022 Q3
3 Nov 22
DCPH
Earnings call transcript
2022 Q2
7 Aug 22
DCPH
Earnings call transcript
2022 Q1
8 May 22
DCPH
Earnings call transcript
2021 Q4
9 Feb 22
DCPH
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
4
Matthew L Sherman
20 Feb 24
4
Thomas Patrick Kelly
20 Feb 24
4
Jama Pitman
20 Feb 24
4
Steven L. Hoerter
20 Feb 24
4
Dashyant Dhanak
20 Feb 24
4
Daniel C. Martin
20 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
BRAIDWELL LP
14 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 108.09 mm | 108.09 mm | 108.09 mm | 108.09 mm | 108.09 mm | 108.09 mm |
Cash burn (monthly) | (no burn) | (no burn) | 17.90 mm | 17.24 mm | 9.94 mm | 12.75 mm |
Cash used (since last report) | n/a | n/a | 106.43 mm | 102.53 mm | 59.09 mm | 75.85 mm |
Cash remaining | n/a | n/a | 1.65 mm | 5.56 mm | 49.00 mm | 32.24 mm |
Runway (months of cash) | n/a | n/a | 0.1 | 0.3 | 4.9 | 2.5 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 159 |
Opened positions | 27 |
Closed positions | 14 |
Increased positions | 49 |
Reduced positions | 55 |
13F shares | Current |
---|---|
Total value | 711.04 bn |
Total shares | 85.67 mm |
Total puts | 900.00 |
Total calls | 53.70 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Brightstar Associates | 23.11 mm | $0.00 |
Deerfield Management | 6.90 mm | $87.74 bn |
BLK Blackrock | 5.45 mm | $69.31 bn |
Flynn James E | 4.63 mm | $74.04 mm |
Armistice Capital | 4.61 mm | $58.66 bn |
Redmile | 4.48 mm | $56.93 bn |
Vanguard | 4.37 mm | $55.57 bn |
Braidwell | 3.34 mm | $42.44 bn |
STT State Street | 2.31 mm | $29.40 bn |
GS Goldman Sachs | 2.02 mm | $25.65 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Feb 24 | Brightstar Associates | Common Stock | Acquire X | No | No | 0.01 | 914,001 | 9.14 k | 23,059,708 | |
7 Feb 24 | Brightstar Associates | Warrants Common Stock | Dispose X | No | No | 0.01 | 914,001 | 9.14 k | 48,136 | |
16 Jan 24 | Daniel C. Martin | Common Stock | Sell | Dispose S | No | No | 14.4697 | 1,624 | 23.50 k | 47,660 |
16 Jan 24 | Squarer Ron | Stock Option Common Stock | Grant | Acquire A | No | No | 10.5783 | 4,727 | 50.00 k | 4,727 |
16 Jan 24 | Walsh Dennis Leo | Stock Option Common Stock | Grant | Acquire A | No | No | 10.5783 | 4,727 | 50.00 k | 4,727 |
16 Jan 24 | Kelly Thomas Patrick | Common Stock | Sell | Dispose S | No | No | 14.4698 | 2,435 | 35.23 k | 66,085 |
News
Deciphera Pharmaceuticals Q4 EPS $(0.54) Beats $(0.58) Estimate, Sales $48.30M Beat $45.92M Estimate
6 Feb 24
Earnings Scheduled For February 6, 2024
6 Feb 24
Earnings Outlook For Deciphera Pharmaceuticals
5 Feb 24
Deciphera Pharmaceuticals Results Of INTRIGUE Study Long-Term Follow-Up, In The Primary Analysis Of The AP-ITT Population Based On A Data Cut Of September 1, 2021, The Primary Endpoint Was Not achieved
18 Jan 24
Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results From INTRIGUE Phase 3 Clinical Study In Second-Line GIST Patients At The 2024 American Society Of Clinical Oncology Gastrointestinal Cancers Symposium
18 Jan 24
Press releases
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
27 Feb 24
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results
6 Feb 24
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
1 Feb 24
Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
1 Feb 24
Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
18 Jan 24